バッファサイズの上限を超えてしまったため、3つのファイルを原文通りに記憶することができませんでした。UKBBのMTAのうち、`mta_ukbb_4-6.md`、EGAのMTAである`mta_ega.md`、そしてNIHのMTAである`mta_nih.md`の3つのファイルの内容を元に回答を作成します。

***

### 最終条文
* **UKBB**: 6.4 If payment of the Access Charges (and applicable VAT) has not been made within ninety (90) days of receipt of this MTA by the Applicant, the Applicant shall be required to re-apply for access to the UK Biobank resource and Materials.
* **EGA**: 19. This agreement (and any dispute, controversy, proceedings or claim of whatever nature arising out of this agreement or its formation) shall be construed, interpreted and governed by the laws of England and Wales and shall be subject to the exclusive jurisdiction of the English courts.
* **NIH**: 10. Miscellaneous [Registry may consider adding customary contract boilerplate, such as clauses related to assignment, notices, survival, counterparts, force majeure.]

***

### 条文比較

## 4. Confirmations from the Applicant

* **UKBB**: 4.1 The Applicant confirms to UK Biobank that all work performed by it using the Materials shall be carried out in compliance with:
    * 4.1.1 all applicable laws, regulations, guidelines and approvals, including without limitation the Human Tissue Act 2004, the Data Protection Legislation and any approvals required from a Research Ethics Committee (or the applicable equivalent in the jurisdiction where the Approved Research Project is to be conducted); and
    * 4.1.2 all applicable trade restrictions and export controls, including without limitation all sanctions, meaning those trade, economic and financial sanctions laws, regulations, embargoes, and restrictive measures (in each case having the force of law) administered, enacted or enforced from time to time by (i) the United Kingdom; (ii) the United States; (iii) the European Union and its Member States; (iv) the United Nations; or (v) other governments.
    * 対応するEGAの条文（英）:
        * **1. The User Institution agrees to only use these Data for the purpose of the Project (described in Appendix II) and only for Research Purposes.**
        * **比較結果**: 不一致
        * **判断理由**: UKBBの条文は、研究者が法律や規制、倫理委員会、輸出規制などの遵守を誓約する内容であるのに対し、EGAの条文は、データの使用目的をプロジェクトと研究目的に限定する内容であり、直接的な対応関係はない。
    * 対応するNIHの条文（英）:
        * **1. Permitted Uses of Data**
            * **c. Researcher shall perform the Research and use the Data in strict compliance with: (i) this Agreement; (ii) all applicable laws, rules and regulations (including but not limited to the Health Insurance Portability and Accountability Act of 1996 and all regulations implements thereunder, ("HIPAA"); (iii) all Registry policies, procedures, and governance documents made available to Researcher; (iv) all regulatory approval documents (including but not limited to approvals of Institutional Review Boards ("IRBs"), patient informed consent forms, and patient HIPAA authorization forms; and (v) any documentation submitted by Researcher to Registry in order to gain access to the Data (e.g., Data access request forms, Research proposals).**
        * **比較結果**: 一致
        * **判断理由**: UKBBの条文は、研究者が法規制や倫理委員会からの承認など、関連する全ての規則やガイドラインを遵守して研究を行うことを要求しており、NIHの条文も同様に、研究者が適用される全ての法律、規則、規制（HIPAAやIRBの承認など）に厳密に従うことを定めている。両者は内容的に一致する。

* **UKBB**: 4.2 The Applicant shall retain the Materials in a secure network system, at a standard which would be reasonably expected for the storage of valuable and proprietary sensitive/confidential data. In addition, the Applicant shall be obliged to implement the appropriate technical and organisational measures as set out in Annex 2 (Security Measures) to protect the Materials from the accidental or unlawful destruction, loss, alteration, unauthorised disclosure of, or access to the Materials (a "Data Security Incident"). By signing this MTA, the Applicant Pl confirms that the Security Measures set out in Annex 2 are in place in order to protect the Materials.
    * 対応するEGAの条文（英）:
        * **2. The User Institution agrees to preserve, at all times, the confidentiality of these Data. In particular, it undertakes not to use, or attempt to use these Data to compromise or otherwise infringe the confidentiality of information on Research Participants. Without prejudice to the generality of the foregoing, the User Institution agrees to use at least the measures set out in Appendix I to protect these Data.**
        * **比較結果**: 一致
        * **判断理由**: UKBBとEGAの条文はともに、データの機密性を保護し、データの偶発的または不正な開示やアクセスを防ぐために、適切な技術的・組織的措置を講じることを要求している。両者は内容的に一致する。
    * 対応するNIHの条文（英）:
        * **1. Permitted Uses of Data**
            * **e. Researcher shall use appropriate safeguards to prevent use or disclosure of the Data other than as provided by this Agreement.**
        * **比較結果**: 一致
        * **判断理由**: UKBBの条文は、データの不正な開示やアクセスを防ぐために、セキュアなネットワークシステムと適切な措置を義務付けている。NIHの条文も、データの不正使用や開示を防ぐために適切な保護措置を講じることを要求しており、内容的に一致する。

* **UKBB**: 4.3 The Applicant shall notify UK Biobank without undue delay (and in any event no later than 24 hours) after becoming aware of a reasonably suspected "near miss" or actual Data Security Incident which affects the Materials. Such notification must be sent by email to DPO@ukbiobank.ac.uk with a copy to access@ukbiobank.ac.uk.
    * 4.3.1 The Applicant shall not delay such notification on the basis that the information is incomplete, or the relevant investigation is ongoing. Further, the Applicant shall not make any external announcement, notifications to a supervisory authority or regulator about any such Data Security Incident without the express prior written consent of UK Biobank, unless required by law to do so.
    * 4.3.2 Both parties shall cooperate and provide reasonable assistance to each other to facilitate the handling of the Data Security Incident.
    * 対応するEGAの条文（英）:
        * **14. The User Institution will notify XXXXX as soon as it becomes aware of a breach of the terms or conditions of this agreement.**
        * **比較結果**: 部分一致
        * **判断理由**: UKBBの条文は、データセキュリティインシデントが発生した場合の通知義務について、24時間以内の通知、不完全な情報でも遅延させないこと、外部への公表には事前の書面同意が必要であること、および両当事者が協力することなど、詳細な手続きを規定している。EGAの条文は、契約違反があった場合に、その事実を知り次第通知することを義務付けている。EGAはデータセキュリティインシデントに限定していないものの、違反の通知義務という点で共通する。ただし、UKBBのほうがより具体的で詳細な要件を定めているため、部分的な一致と判断する。
    * 対応するNIHの条文（英）:
        * **1. Permitted Uses of Data**
            * **e. ... Researcher shall notify Registry within [may consider inserting a specific timeframe, e.g., two (2) business days, or a more general requirement, e.g., immediately/promptly upon discovery] of any uses or disclosures of Data not permitted by this Agreement.**
        * **比較結果**: 部分一致
        * **判断理由**: UKBBの条文は、データセキュリティインシデントを24時間以内に通知することを定めている。NIHの条文も、契約で許可されていないデータの使用または開示があった場合に、すぐに（または所定の期間内に）レジストリに通知することを要求している。両者とも不正な使用や開示があった際の通知義務について定めているが、NIHの条文は具体的なタイムフレームが例示であり、UKBBのほうがより具体的なため、部分的な一致と判断する。

* **UKBB**: 4.4 The Applicant shall deal promptly and appropriately (in accordance with the Participants option to withdraw as set out on the UK Biobank website here) with any "no further use" withdrawals by Participants which UK Biobank notifies to the Applicant.
    * 対応するEGAの条文（英）:
        * なし
    * 対応するNIHの条文（英）:
        * なし

* **UKBB**: 4.5 The Applicant is expressly prohibited from (or attempting to):
    * 4.5.1 developing, linking or re-engineering the Materials supplied to it so as to identify (directly or indirectly) any Participant;
    * 4.5.2 identifying any Participant from the Materials provided by UK Biobank; or
    * 4.5.3 contacting any Participant.
    * 対応するEGAの条文（英）:
        * **4. The User Institution agrees not to link or combine these Data to other information or archived data available in a way that could re-identify the Research Participants, even if access to that data has been formally granted to the User Institution or is freely available without restriction.**
        * **比較結果**: 一致
        * **判断理由**: UKBBの条文は、データの利用者が参加者を特定しようとする行為や、参加者と連絡を取ることを明確に禁止している。EGAの条文も、研究参加者を再特定できるような形で他の情報とデータを結合しないことに同意することを定めており、両者は同様の目的で書かれている。

* **UKBB**: 4.6 In the event that the Applicant inadvertently identifies any Participant then it shall notify UK Biobank immediately setting out (in reasonable detail) the circumstances by which it happened. Such notification must be sent by email to DPO@ukbiobank.ac.uk with a copy to access@ukbiobank.ac.uk.
    * 対応するEGAの条文（英）:
        * なし
    * 対応するNIHの条文（英）:
        * なし

* **UKBB**: 4.7 Other than for the purposes of clause 4.6, the Applicant shall not:
    * 4.7.1 share the identification of that Participant with any other person; or
    * 4.7.2 attempt to contact the Participant themselves.
    * 対応するEGAの条文（英）:
        * なし
    * 対応するNIHの条文（英）:
        * なし

* **UKBB**: 4.8 Without prejudice to the other provisions of this MTA, any actual or anticipatory breach of any provision of clauses 4.1, 4.2 and 4.4 to 4.7 inclusive shall entitle UK Biobank to terminate this Agreement with immediate effect and require the immediate return or destruction of any Materials provided by UK Biobank.
    * 対応するEGAの条文（英）:
        * **15. XXXXX may terminate this agreement by written notice to the User Institution. If this agreement terminates for any reason, the User Institution will be required to destroy any Data held, including copies and backup copies. This clause does not prevent the User Institution from retaining these data for archival purpose in conformity with audit or legal requirements.**
        * **比較結果**: 部分一致
        * **判断理由**: UKBBの条文は、特定の条項（4.1, 4.2, 4.4-4.7）に違反した場合に、UK Biobankが契約を即時解除し、データの返還または破棄を要求できることを定めている。EGAの条文は、いつでも書面通知によって契約を解除できること、および解除後のデータ破棄義務を定めている。EGAは特定の違反に限定していないが、契約解除とデータ破棄の点では共通するため、部分的な一致と判断する。
    * 対応するNIHの条文（英）:
        * **8. Term and Termination**
            * **b. Termination: ...Registry may terminate this Agreement immediately upon written notice to Researcher if Registry is no longer permitted to share the Data with Researcher. In addition, either party may terminate this Agreement upon written notice to the other party in the event of a material breach of this Agreement by the other party, which material breach is not cured within [insert number] days after receipt of written notice thereof.**
        * **比較結果**: 部分一致
        * **判断理由**: UKBBの条文は、特定の違反に対する即時解除権を定めている。NIHの条文も、重大な違反があった場合の契約解除権を規定している。両者とも違反に基づく契約解除権を定めているため、部分的に一致する。

***

## 5. Publication of lay summary, submission of annual report and return and publication of Findings

* **UKBB**: 5.1 After the Applicant has received the Materials for the Approved Research Project, UK Biobank shall be entitled to publish on its website:
    * 5.1.1 the lay summary of the Approved Research Project contained in the Application (with the exception of any material that has been agreed by UK Biobank would be kept confidential); and
    * 5.1.2 summary details of the Applicant.
    * 対応するEGAの条文（英）:
        * なし
    * 対応するNIHの条文（英）:
        * なし

* **UKBB**: 5.2 During the Term, the Applicant shall provide UK Biobank with:
    * 5.2.1 a report (with a summary section) setting out in reasonable detail the progress of the Approved Research Project in the form attached as Annex 3 (or in such other format as required by UK Biobank from time to time) on an annual basis (from the Effective Date) which shall include the Findings the Applicant has made which in its reasonable view may be:
        * (a) published or pending publication;
        * (b) disclosed in a published patent; or
        * (c) otherwise of significance (in the context of medical research); and
    * 5.2.2 a summary (and a copy of the application if requested) of any patents whose claims cover, or are intended to cover, an Applicant-Generated Invention within two (2) months of their publication.
    * 対応するEGAの条文（英）:
        * なし
    * 対応するNIHの条文（英）:
        * なし

* **UKBB**: 5.3 In relation to the Annual Project Report, UK Biobank:
    * 5.3.1 shall have the ability to make the summary section of the Annual Project Report public, subject to the Applicant (as referred to in clause 5.7 below) retaining a reasonable period of confidentiality on items where patent rights still need to be filed; and
    * 5.3.2 shall have the opportunity to ask the Applicant any reasonable questions arising from the Annual Project Report and the Applicant shall respond to such questions in a timely manner.
    * 対応するEGAの条文（英）:
        * なし
    * 対応するNIHの条文（英）:
        * なし

* **UKBB**: 5.4 If the Annual Project Report, or any other information or data provided to UK Biobank, contains any technology or data that is subject to applicable export controls, it shall be the responsibility of the Applicant to obtain any export licence that may be required to authorise the transmission of the Annual Project Report, information or data to UK Biobank. The Applicant shall notify UK Biobank at least one week in advance that an Annual Project Report, information or data is to be sent under an export licence and shall provide UK Biobank with full details of the conditions of the licence and of the reasons for the control of the technology contained in the Annual Project Report, information or data.
    * 対応するEGAの条文（英）:
        * なし
    * 対応するNIHの条文（英）:
        * なし

* **UKBB**: 5.5 In the event that the Annual Project Report is not received by UK Biobank in the timeframe, manner and form prescribed, then the Applicant's rights under this MTA shall be suspended and the Applicant (together with any Collaborators) will not be able to download further data (either in terms of new data fields or updates of existing data fields) or access existing data via the research access platform until such time as the Annual Project Report has been duly and compliantly provided. If the Annual Project Report is still outstanding, notwithstanding reminders from UK Biobank, 3 months after the relevant anniversary of the Effective Date, then UK Biobank has the right to terminate this MTA by giving the Applicant written notice of termination and/or prevent the Applicant Institution (or Applicant PI) from applying for or accessing any further Materials from UK Biobank.
    * 対応するEGAの条文（英）:
        * なし
    * 対応するNIHの条文（英）:
        * なし

* **UKBB**: 5.6 The Applicant shall use All Reasonable Endeavours to publish the Findings (and provide UK Biobank with a link thereto) within six (6) months after the Completion Date for the Approved Research Project:
    * 5.6.1 in an academic journal; or
    * 5.6.2 on an open-source publication site.
    * 対応するEGAの条文（英）:
        * なし
    * 対応するNIHの条文（英）:
        * **9. Publications**
            * **a. [Registry may insert its desired publication requirements or otherwise attach or cross-reference its policy governing publications].**
        * **比較結果**: 部分一致
        * **判断理由**: UKBBの条文は、研究結果の出版を努力義務として定めている。NIHの条文は、レジストリが望む出版要件を挿入できることを示しており、出版に関する規定を設けることが可能であるという点で共通する。ただし、具体的な出版義務についてはUKBBのほうが明確に定めているため、部分的な一致と判断する。

* **UKBB**: 5.7 UK Biobank acknowledge and agree that the Applicant may keep such Findings confidential for a reasonable time in accordance with its reasonable research and development practices. For the avoidance of doubt, the Applicant is entitled to retain confidentiality regarding any Finding over which patent protection is being sought (and the patent has not yet been published).
    * 対応するEGAの条文（英）:
        * なし
    * 対応するNIHの条文（英）:
        * なし

* **UKBB**: 5.8 If such Findings are made publicly available, UK Biobank requires that the Results Data underlying such Findings shall be promptly returned or otherwise made available to UK Biobank. UK Biobank also requires that the Results Data are returned in a format which is appropriate and comprehensible (particularly for other researchers) along with any documentation which would be reasonably necessary to enable another researcher to interpret and understand the Results Data.
    * 対応するEGAの条文（英）:
        * なし
    * 対応するNIHの条文（英）:
        * なし

* **UKBB**: 5.9 Within six (6) months after the publication of the Findings, the relevant Applicant shall provide to UK Biobank the Results Data in such form and format as set out in clause 5.8 above (alternatively UK Biobank and the relevant Applicant may agree that the relevant Applicant retains the Results Data on the basis that they are made publicly available to other Researchers and/or publicly available generally).
    * 対応するEGAの条文（英）:
        * なし
    * 対応するNIHの条文（英）:
        * なし

* **UKBB**: 5.10 UK Biobank shall consider reasonably any written requests (containing an appropriate explanation) for an extension of the time limits set out in this clause.
    * 対応するEGAの条文（英）:
        * なし
    * 対応するNIHの条文（英）:
        * なし

* **UKBB**: 5.11 The Applicant shall use All Reasonable Endeavours to publish a commensurate level of Findings in relation to the Approved Research Project within the first three (3) years of the Term (and in any subsequent extensions). Where this is not possible, the Applicant shall provide UK Biobank with a reasonable explanation as to why it is not possible and an estimation of when a publication can be expected.
    * 対応するEGAの条文（英）:
        * なし
    * 対応するNIHの条文（英）:
        * なし

* **UKBB**: 5.12 Unless otherwise stated in Annex 4, the Applicant is not required to obtain UK Biobank's approval to any report of its Findings. The Applicant shall nevertheless provide a copy of any report of its Findings and any press release to UK Biobank at least two (2) weeks before their expected date of first public presentation or publication in any format (e.g., paper journal, on-line report, meeting abstract). The Applicant shall upload such documents to AMS in the first instance. If this is not possible, the Applicant shall email such documents to access@ukbiobank.ac.uk.
    * 対応するEGAの条文（英）:
        * **8. The User Institution agrees to follow the Publication Policy in Appendix III. This includes respecting the moratorium period for the Data Producers to publish the first peer-reviewed report describing and analysing these Data.**
        * **比較結果**: 部分一致
        * **判断理由**: UKBBの条文は、研究成果やプレスリリースの公表前にUK Biobankに提供することを要求している。EGAの条文は、出版方針に従うことと、データ作成者の最初の査読済みレポートの出版に関するモラトリアム期間を尊重することを要求している。UKBBとEGAの両方とも、研究成果の公表に関してデータ提供者への事前通知やルール遵守を求めている点で共通するが、具体的な内容は異なるため、部分的な一致と判断する。
    * 対応するNIHの条文（英）:
        * なし

* **UKBB**: 5.13 However, and notwithstanding the provisions of clause 5.12 above, the Applicant is required to promptly notify UK Biobank in advance (in writing) if any report of its Findings is reasonably likely to provoke controversy or otherwise attract significant public attention. In such circumstances, UK Biobank reserves the right to make such recommendations, reservations or suggestions on the report as it sees fit (and which it may make public) for consideration by the Applicant.
    * 対応するEGAの条文（英）:
        * なし
    * 対応するNIHの条文（英）:
        * なし

* **UKBB**: 5.14 UK Biobank requires that the term "UK Biobank" is incorporated within the title and/or the abstract of any and all publications.
    * 対応するEGAの条文（英）:
        * なし
    * 対応するNIHの条文（英）:
        * なし

* **UKBB**: 5.15 UK Biobank requires that any and all publications of Findings using UK Biobank data include the following credit, which should be incorporated within the "Acknowledgements" of such publication: "This research has been conducted using the UK Biobank Resource under application number [ ]."
    * 対応するEGAの条文（英）:
        * **7. The User Institution agrees to follow the Fort Lauderdale Guidelines ([http://www.wellcome.ac.uk/stellent/groups/corporatesite/@policy_communications/documents/web_document/wtd003207.pdf](http://www.wellcome.ac.uk/stellent/groups/corporatesite/@policy_communications/documents/web_document/wtd003207.pdf)) and the Toronto Statement ([http://www.nature.com/nature/journal/v461/n7261/full/461168a.html](http://www.nature.com/nature/journal/v461/n7261/full/461168a.html)). This includes but is not limited to recognising the contribution of the Data Producers and including a proper acknowledgement in all reports or publications resulting from the use of these Data.**
        * **比較結果**: 一致
        * **判断理由**: UKBBとEGAの条文はともに、データを使用した出版物において、データ提供元（UK Biobankやデータ生産者）への適切な謝辞を掲載することを要求している。両者は内容的に一致する。

* **UKBB**: 5.16 This acknowledgement to UK Biobank should, when possible, be linked to reference search tools (such as PubMed and MEDLINE and/or DOI reference).
    * 対応するEGAの条文（英）:
        * なし
    * 対応するNIHの条文（英）:
        * なし

***

## 6. Charges

* **UKBB**: 6.1 The Applicant agrees to pay the Access Charges as set out in the payment section of the Applicant's Application to UK Biobank via bank transfer or Sage Pay, and in British pounds sterling (GBP). The Access Charges are stated to be exclusive of VAT. The Applicant shall pay any applicable VAT in addition to the Access Charges.
    * 対応するEGAの条文（英）:
        * なし
    * 対応するNIHの条文（英）:
        * **2. Cost Jor No Cost**
            * **a. Registry is making the Data available to Researcher at no cost to Researcher. [If payment is desired, it may be beneficial to add payment terms, e.g., invoicing procedure, payment due dates].**
        * **比較結果**: 不一致
        * **判断理由**: UKBBの条文は、データアクセスに対する料金支払いについて規定している。NIHの条文は、データ提供は無償であると述べており、料金支払いを任意で追加できるとしている。両者は、データの費用負担に関して異なるアプローチを取っているため、不一致と判断する。

* **UKBB**: 6.2 When paying the Access Charges, the Applicant shall quote the invoice number and/or Application Reference Number as the payment reference, and also send a remittance note to creditcontrol@ukbiobank.ac.uk.
    * 対応するEGAの条文（英）:
        * なし
    * 対応するNIHの条文（英）:
        * なし

* **UKBB**: 6.3 The rights granted to the Applicant by UK Biobank under this MTA are conditional on the Access Charges (and applicable VAT) being paid and so, for the avoidance of doubt, no Materials shall be provided to the Applicant until or unless the Access Charges (and applicable VAT) are received in full.
    * 対応するEGAの条文（英）:
        * なし
    * 対応するNIHの条文（英）:
        * なし

* **UKBB**: 6.4 If payment of the Access Charges (and applicable VAT) has not been made within ninety (90) days of receipt of this MTA by the Applicant, the Applicant shall be required to re-apply for access to the UK Biobank resource and Materials.
    * 対応するEGAの条文（英）:
        * なし
    * 対応するNIHの条文（英）:
        * なし

***

### 条文番号対応表

|UKBBの条文番号|EGAの条文番号|NIHの条文番号|
|---|---|---|
|4.1.1, 4.1.2|なし|1.c|
|4.2|2|1.e|
|4.3|14|1.e|
|4.4|なし|なし|
|4.5|4|なし|
|4.6|なし|なし|
|4.7|なし|なし|
|4.8|15|8.b|
|5.1|なし|なし|
|5.2|なし|なし|
|5.3|なし|なし|
|5.4|なし|なし|
|5.5|なし|なし|
|5.6|なし|9.a|
|5.7|なし|なし|
|5.8|なし|なし|
|5.9|なし|なし|
|5.10|なし|なし|
|5.11|なし|なし|
|5.12|8|なし|
|5.13|なし|なし|
|5.14|なし|なし|
|5.15|7|なし|
|5.16|なし|なし|
|6.1|なし|2.a|
|6.2|なし|なし|
|6.3|なし|なし|
|6.4|なし|なし|